<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>VERVE-101/102 - Gene Editing Therapy | Leaf Intelligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <style>
        /* Custom animations matching Leaf Intelligence style */
        @keyframes fadeInRow {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        @keyframes pulse {
            0%, 100% { opacity: 0.5; transform: scale(0.95); }
            50% { opacity: 0.8; transform: scale(1.1); }
        }
        @keyframes slideIn {
            from { opacity: 0; transform: translateX(-10px); }
            to { opacity: 1; transform: translateX(0); }
        }
        .animate-fade-in-row { animation: fadeInRow 0.3s ease forwards; }
        .animate-pulse-glow { animation: pulse 3s ease-in-out infinite; }
        .animate-slide-in { animation: slideIn 0.6s ease-out forwards; }
        
        /* Staggered animations */
        .stagger-1 { animation-delay: 0.1s; }
        .stagger-2 { animation-delay: 0.2s; }
        .stagger-3 { animation-delay: 0.3s; }
        .stagger-4 { animation-delay: 0.4s; }
        .stagger-5 { animation-delay: 0.5s; }
        
        /* Custom scrollbar */
        ::-webkit-scrollbar { width: 8px; height: 8px; }
        ::-webkit-scrollbar-track { @apply bg-gray-100 dark:bg-gray-800 rounded; }
        ::-webkit-scrollbar-thumb { @apply bg-gray-400 dark:bg-gray-600 rounded hover:bg-gray-500 dark:hover:bg-gray-500; }
        
        /* Glass effect */
        .glass {
            background: rgba(255, 255, 255, 0.75);
            backdrop-filter: blur(20px);
            -webkit-backdrop-filter: blur(20px);
        }
        .dark .glass {
            background: rgba(17, 24, 39, 0.75);
        }
    </style>
</head>
<body class="bg-gray-50 dark:bg-gray-900 transition-all duration-300">
    <!-- Fixed Header - Matching Leaf Intelligence design -->
    <header class="fixed top-0 left-0 right-0 z-50 glass border-b border-gray-200 dark:border-gray-700 shadow-lg">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8">
            <div class="flex justify-between items-center py-4">
                <!-- Logo -->
                <div class="flex items-center space-x-3">
                    <div class="relative">
                        <img src="leaf.png" alt="Leaf Intelligence" class="h-12 w-12 relative z-10">
                        <div class="absolute inset-0 bg-gradient-to-r from-green-400 to-cyan-400 opacity-20 blur-xl animate-pulse-glow"></div>
                    </div>
                    <div>
                        <div class="text-xl font-light bg-gradient-to-r from-green-600 to-cyan-600 dark:from-green-400 dark:to-cyan-400 bg-clip-text text-transparent">
                            Leaf Intelligence
                        </div>
                        <div class="text-xs text-gray-600 dark:text-gray-400 font-light">
                            Cholesterol Therapies Analysis
                        </div>
                    </div>
                </div>

                <!-- Navigation -->
                <nav class="hidden md:flex items-center space-x-1 bg-gray-100/50 dark:bg-gray-800/50 p-1.5 rounded-lg backdrop-blur-sm">
                    <a href="index.html" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Overview
                    </a>
                    <button class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 bg-white dark:bg-gray-700 text-indigo-600 dark:text-indigo-400 shadow-md active">
                        Drug Profile
                    </button>
                    <a href="index.html#comparison" class="nav-tab px-5 py-2 rounded-md text-sm font-medium transition-all duration-200 text-gray-600 dark:text-gray-400 hover:text-gray-900 dark:hover:text-white hover:bg-white/50 dark:hover:bg-gray-700/50">
                        Comparison
                    </a>
                </nav>

                <!-- Theme Toggle -->
                <!-- <button onclick="toggleTheme()" class="relative w-14 h-7 rounded-full bg-gray-200 dark:bg-gray-700 transition-all duration-300 shadow-inner hover:shadow-md">
                    <div class="absolute top-0.5 left-0.5 w-6 h-6 rounded-full bg-white dark:bg-gray-900 shadow-lg transform transition-transform duration-300 dark:translate-x-7 flex items-center justify-center">
                        <svg class="w-4 h-4 text-yellow-500 dark:hidden" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M12 7a5 5 0 100 10 5 5 0 000-10z"/>
                        </svg>
                        <svg class="w-4 h-4 text-indigo-400 hidden dark:block" fill="currentColor" viewBox="0 0 24 24">
                            <path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/>
                        </svg>
                    </div>
                </button> -->
            </div>
        </div>
    </header>

    <!-- Main Container with padding for fixed header -->
    <div class="pt-20 min-h-screen">
        <div class="max-w-7xl mx-auto px-4 sm:px-6 lg:px-8 py-8">
            
            <!-- Hero Section -->
            <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-col md:flex-row justify-between items-start md:items-center gap-4">
                    <div>
                        <h1 class="text-4xl font-light mb-2 text-gray-900 dark:text-white">
                            VERVE-101 / VERVE-102
                        </h1>
                        <p class="text-lg text-gray-600 dark:text-gray-400">
                            First-in-Class In Vivo Base Editing Therapy • Verve Therapeutics → Eli Lilly
                        </p>
                    </div>
                    <div class="flex flex-wrap gap-2">
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-red-500 to-pink-500 text-white">
                            Phase 1 - Paused/Pivoted
                        </span>
                        <span class="inline-flex items-center px-4 py-2 rounded-full text-sm font-medium bg-gradient-to-r from-green-500 to-emerald-500 text-white">
                            Lilly Acquisition $1B
                        </span>
                    </div>
                </div>
            </div>

            <!-- Key Metrics Grid -->
            <div class="grid grid-cols-1 md:grid-cols-2 lg:grid-cols-4 gap-6 mb-8">
                <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                    <div class="text-3xl font-bold bg-gradient-to-r from-purple-600 to-pink-600 bg-clip-text text-transparent mb-2">
                        One-Time
                    </div>
                    <div class="text-sm text-gray-600 dark:text-gray-400">Treatment Paradigm</div>
                    <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Permanent gene edit</div>
                </div>
                <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                    <div class="text-3xl font-bold bg-gradient-to-r from-indigo-600 to-purple-600 bg-clip-text text-transparent mb-2">
                        50-70%
                    </div>
                    <div class="text-sm text-gray-600 dark:text-gray-400">LDL Reduction</div>
                    <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">Permanent effect</div>
                </div>
                <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                    <div class="text-3xl font-bold bg-gradient-to-r from-amber-600 to-orange-600 bg-clip-text text-transparent mb-2">
                        2028-2030
                    </div>
                    <div class="text-sm text-gray-600 dark:text-gray-400">Potential Approval</div>
                    <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">If Phase 3 succeeds</div>
                </div>
                <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 hover:shadow-lg transition-shadow">
                    <div class="text-3xl font-bold bg-gradient-to-r from-green-600 to-emerald-600 bg-clip-text text-transparent mb-2">
                        $1-2M
                    </div>
                    <div class="text-sm text-gray-600 dark:text-gray-400">Expected Price</div>
                    <div class="text-xs text-gray-500 dark:text-gray-500 mt-1">One-time cost</div>
                </div>
            </div>

            <!-- Tab Navigation -->
            <div class="glass rounded-2xl mb-8 border border-gray-200 dark:border-gray-700">
                <div class="flex flex-wrap gap-1 p-2">
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-indigo-600 text-white" onclick="showTab('overview', event)">
                        Overview
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('technology', event)">
                        Technology
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('regulatory', event)">
                        Regulatory
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('clinical', event)">
                        Clinical Trials
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('safety', event)">
                        Safety
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('commercial', event)">
                        Commercial
                    </button>
                    <button class="tab-btn px-6 py-3 rounded-lg text-sm font-medium transition-all bg-gray-100 dark:bg-gray-800 text-gray-700 dark:text-gray-300 hover:bg-gray-200 dark:hover:bg-gray-700" onclick="showTab('future', event)">
                        Future Outlook
                    </button>
                </div>
            </div>

            <!-- Overview Tab -->
            <div class="tab-content active" id="overview">
                <!-- Paradigm Shift Alert -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-red-50 to-pink-50 dark:from-red-900/20 dark:to-pink-900/20">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-3">
                        🎯 Paradigm Shift Alert
                    </h3>
                    <p class="text-gray-700 dark:text-gray-300 leading-relaxed">
                        One-time IV infusion permanently inactivates PCSK9 gene in liver cells, potentially providing lifelong LDL-C reduction. 
                        This is not a drug - it's a functional cure for high cholesterol through precise DNA editing.
                    </p>
                    <div class="mt-4">
                        <a href="https://clinicaltrials.gov/study/NCT05398029" 
                           target="_blank" 
                           class="inline-flex items-center text-sm text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 dark:hover:text-indigo-300">
                            View Clinical Trial Data →
                        </a>
                    </div>
                </div>

                <!-- Key Information Cards -->
                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8 mb-8">
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm">🧬</span>
                            What is VERVE-101/102?
                        </h3>
                        <p class="text-sm text-gray-600 dark:text-gray-400 mb-4">
                            An investigational gene-editing therapy using CRISPR-derived base-editing technology to permanently reduce cholesterol. 
                            It makes a single-letter change in the DNA of liver cells to turn off PCSK9 production forever.
                        </p>
                        <ul class="space-y-2">
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">•</span>
                                Uses adenine base editor (ABE) - no double-strand DNA breaks
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">•</span>
                                Delivered via lipid nanoparticle (LNP) to liver
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">•</span>
                                Single IV infusion intended to last a lifetime
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400 flex items-start">
                                <span class="text-green-500 mr-2 mt-1">•</span>
                                Mimics natural PCSK9 mutations that protect against heart disease
                            </li>
                        </ul>
                    </div>

                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="flex items-center gap-2 mb-4 text-lg font-medium text-gray-900 dark:text-white">
                            <span class="w-8 h-8 bg-gradient-to-r from-amber-600 to-orange-600 rounded-full flex items-center justify-center text-white text-sm">📊</span>
                            Current Status
                        </h3>
                        <ul class="space-y-3">
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">VERVE-101:</strong> Paused April 2024 due to safety concerns (liver enzyme elevation, low platelets)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">VERVE-102:</strong> Improved version with better LNP formulation, IND cleared March 2025
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Heart-2 Trial:</strong> Starting H2 2025 with VERVE-102
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Lilly Acquisition:</strong> Completed July 25, 2025 for ~$1 billion
                            </li>
                        </ul>
                        <div class="mt-4 pt-4 border-t border-gray-200 dark:border-gray-700">
                            <a href="https://investors.vrtx.com/news-releases" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800">
                                View Press Releases →
                            </a>
                        </div>
                    </div>
                </div>

                <!-- Pipeline Programs -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Pipeline Programs</h3>
                    <div class="grid grid-cols-1 md:grid-cols-3 gap-6">
                        <div class="bg-gradient-to-r from-indigo-100 to-purple-100 dark:from-indigo-900/30 dark:to-purple-900/30 p-6 rounded-lg border-2 border-indigo-500 dark:border-indigo-400 shadow-md">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">VERVE-102</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mb-2">PCSK9 (HeFH/ASCVD)</div>
                            <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400">Phase 1b/2 Starting</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 p-6 rounded-lg border border-gray-200 dark:border-gray-600 hover:shadow-md transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">VERVE-201</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mb-2">ANGPTL3 (HoFH)</div>
                            <div class="text-xs font-medium text-gray-500">IND-Enabling</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 p-6 rounded-lg border border-gray-200 dark:border-gray-600 hover:shadow-md transition-shadow">
                            <div class="text-lg font-medium text-gray-900 dark:text-white mb-2">VERVE-301</div>
                            <div class="text-sm text-gray-600 dark:text-gray-400 mb-2">Lp(a) Reduction</div>
                            <div class="text-xs font-medium text-gray-500">Research Stage</div>
                        </div>
                    </div>
                </div>

                <!-- Competitive Positioning Table -->
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">Competitive Positioning</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Approach</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Frequency</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">LDL Reduction</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Reversibility</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Market Timeline</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="bg-amber-50 dark:bg-amber-900/10 hover:bg-amber-100 dark:hover:bg-amber-900/20 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">VERVE Gene Editing</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Once lifetime</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">50-70%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Irreversible</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2028-2030</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white">Inclisiran (siRNA)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2x/year</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">50%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Reversible</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white">PCSK9 mAbs</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Monthly</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Reversible</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Approved</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm text-gray-900 dark:text-white">Oral PCSK9i</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Daily</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">60%</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Reversible</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">2026-2027</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- Technology Tab -->
            <div class="tab-content hidden" id="technology">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">How Base Editing Works</h3>
                    
                    <div class="grid grid-cols-2 md:grid-cols-3 lg:grid-cols-6 gap-4 mb-6">
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">1</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Delivery</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">LNP carries mRNA for base editor + guide RNA to liver via IV</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">2</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Targeting</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">Guide RNA directs editor to PCSK9 gene in hepatocytes</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">3</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Editing</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">ABE makes precise A→G change without cutting DNA</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">4</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Result</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">Introduces stop codon, halting PCSK9 production</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">5</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Effect</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">50-70% of liver cells edited, 80-90% PCSK9↓</div>
                        </div>
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="w-8 h-8 bg-gradient-to-r from-indigo-600 to-purple-600 rounded-full flex items-center justify-center text-white text-sm font-medium mb-3">6</div>
                            <div class="text-xs font-medium text-gray-900 dark:text-white mb-1">Outcome</div>
                            <div class="text-xs text-gray-500 dark:text-gray-400">50-70% LDL reduction sustained indefinitely</div>
                        </div>
                    </div>

                    <div class="bg-gray-50 dark:bg-gray-800 rounded-lg p-6">
                        <h4 class="font-medium text-gray-900 dark:text-white mb-4">Technical Specifications</h4>
                        <ul class="space-y-2">
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Editor Type:</strong> Adenine Base Editor (ABE) - Cas9 nickase + TadA deaminase
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Target:</strong> PCSK9 gene exon 1 - introduces premature stop codon
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Delivery:</strong> Liver-targeted LNP (similar to COVID vaccines but optimized)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Editing Efficiency:</strong> 50-70% of hepatocytes at therapeutic doses
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Off-target Rate:</strong> <0.1% genome-wide (WGS validated)
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Germline Risk:</strong> Minimal - no gonadal LNP distribution shown
                            </li>
                        </ul>
                    </div>
                </div>

                <!-- VERVE-101 vs VERVE-102 Comparison -->
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">VERVE-101 vs VERVE-102</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Feature</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">VERVE-101</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">VERVE-102 (Improved)</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">LNP Formulation</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">First-generation LNP</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">GalNAc-conjugated (enhanced liver targeting)</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Status</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-red-100 dark:bg-red-900/30 text-red-800 dark:text-red-400">
                                            Paused April 2024
                                        </span>
                                    </td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                            IND Cleared March 2025
                                        </span>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Tolerability</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Grade 3 ALT elevations, thrombocytopenia</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Expected improved safety profile</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Dosing</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">0.1-0.6 mg/kg tested</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Potentially lower doses needed</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Trial</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Heart-1 (paused)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Heart-2 (starting H2 2025)</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- Regulatory Tab -->
            <div class="tab-content hidden" id="regulatory">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-amber-50 to-orange-50 dark:from-amber-900/20 dark:to-orange-900/20">
                    <p class="text-gray-700 dark:text-gray-300">
                        <span class="text-lg mr-2">⚠️</span>
                        As the first in vivo base editing therapy, VERVE faces unprecedented regulatory scrutiny. Every step sets precedent for the entire field.
                    </p>
                </div>

                <!-- FDA Regulatory Timeline -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">FDA Regulatory Timeline</h3>
                    
                    <div class="relative pl-8">
                        <!-- Timeline line -->
                        <div class="absolute left-3 top-0 bottom-0 w-0.5 bg-gradient-to-b from-transparent via-indigo-300 dark:via-indigo-600 to-transparent"></div>
                        
                        <!-- Timeline items -->
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">OCTOBER 2022</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">IND Submission</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    First IND for in vivo base editing submitted to FDA
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-red-600 dark:text-red-400 mb-1">NOVEMBER 2022</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">FDA Clinical Hold</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Concerns: germline editing, off-targets, potency, LNP safety
                                </div>
                                <a href="https://www.fda.gov/news-events/fda-newsroom" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    View FDA Updates →
                                </a>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-indigo-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-indigo-600 dark:text-indigo-400 mb-1">2022-2023</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Ex-US Trial Start</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Trials began in New Zealand and UK while FDA hold active
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">OCTOBER 2023</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">FDA Hold Lifted</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Comprehensive safety data satisfied FDA concerns
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-red-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-red-600 dark:text-red-400 mb-1">APRIL 2024</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Voluntary Pause</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Heart-1 paused due to Grade 3 ALT elevation and thrombocytopenia
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">MARCH 2025</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">VERVE-102 IND Cleared</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    FDA approves improved version with better LNP
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-green-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-white dark:bg-gray-800 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-green-600 dark:text-green-400 mb-1">JULY 25, 2025</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Lilly Acquisition</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    $1B deal complete, enhanced resources
                                </div>
                                <a href="https://investor.lilly.com/news-releases" target="_blank" class="text-xs text-indigo-600 dark:text-indigo-400 mt-2 inline-block">
                                    View Announcement →
                                </a>
                            </div>
                        </div>
                        
                        <div class="relative mb-8">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-amber-50 dark:bg-amber-900/20 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">H2 2025 (PROJECTED)</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Heart-2 Start</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    Phase 1b/2 trial initiation expected
                                </div>
                            </div>
                        </div>
                        
                        <div class="relative">
                            <div class="absolute -left-5 w-4 h-4 bg-amber-500 rounded-full border-2 border-white dark:border-gray-900"></div>
                            <div class="ml-6 p-4 bg-amber-50 dark:bg-amber-900/20 rounded-lg shadow-md">
                                <div class="text-xs font-medium text-amber-600 dark:text-amber-400 mb-1">2028-2030 (PROJECTED)</div>
                                <div class="text-sm font-medium text-gray-900 dark:text-white mb-2">Potential BLA</div>
                                <div class="text-xs text-gray-600 dark:text-gray-400">
                                    If Phase 3 successful, multi-year follow-up required
                                </div>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Global Regulatory Status -->
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">Global Regulatory Status</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Region</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Events</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Timeline</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Actions</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">FDA (US)</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                            Phase 1
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Hold lifted, VERVE-102 IND cleared</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">BLA ~2028-2030</td>
                                    <td class="px-6 py-4">
                                        <a href="https://www.fda.gov" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">EMA (EU)</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                            Pre-clinical
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">No hold, more permissive initially</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">MAA ~2030</td>
                                    <td class="px-6 py-4">
                                        <a href="https://www.ema.europa.eu" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">MHRA (UK)</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                            Phase 1
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">First to approve human trials</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Active sites</td>
                                    <td class="px-6 py-4">
                                        <a href="https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Medsafe (NZ)</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                            Phase 1
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Enabled first-in-human dosing</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Active sites</td>
                                    <td class="px-6 py-4">
                                        <a href="https://www.medsafe.govt.nz" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- Clinical Trials Tab -->
            <div class="tab-content hidden" id="clinical">
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700 mb-8">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">Clinical Development Program</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Trial</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Phase</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">N</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Population</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Status</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Key Results</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Data</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Preclinical</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Pre</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">~50</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Non-human primates</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                            Complete
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">89% PCSK9↓, 69% LDL↓ >2.5yr</td>
                                    <td class="px-6 py-4">
                                        <a href="https://pubmed.ncbi.nlm.nih.gov" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Heart-1<br>(NCT05398029)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">1b</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">44 planned<br>~12 dosed</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">HeFH/ASCVD</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-red-100 dark:bg-red-900/30 text-red-800 dark:text-red-400">
                                            Paused
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">83% PCSK9↓, 55% LDL↓<br>Safety issues at 0.6 mg/kg</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov/study/NCT05398029" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">View →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Heart-2<br>(VERVE-102)</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">1b/2</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">~100</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">HeFH/CAD</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                            Starting H2 2025
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">—</td>
                                    <td class="px-6 py-4">
                                        <a href="https://clinicaltrials.gov" target="_blank" class="text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 text-xs">Track →</a>
                                    </td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Long-term Registry</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">4</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">All pts</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">All treated</td>
                                    <td class="px-6 py-4">
                                        <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-amber-100 dark:bg-amber-900/30 text-amber-800 dark:text-amber-400">
                                            Ongoing
                                        </span>
                                    </td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">5-15 year follow-up planned</td>
                                    <td class="px-6 py-4"></td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-blue-50 to-indigo-50 dark:from-blue-900/20 dark:to-indigo-900/20">
                    <p class="text-gray-700 dark:text-gray-300">
                        <span class="text-lg mr-2">📊</span>
                        <strong>No CV Outcomes Trials Yet:</strong> Approval will rely on LDL-C as surrogate endpoint with post-marketing outcomes commitment. 
                        Expected 50-80% lifetime MACE reduction if given early, based on genetic data.
                    </p>
                </div>

                <!-- Efficacy Results -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Heart-1 Interim Data (High Dose Cohort)</h3>
                    
                    <div class="grid grid-cols-2 md:grid-cols-3 lg:grid-cols-6 gap-4 mb-6">
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">83%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">PCSK9<br>Reduction</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">55%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">LDL-C Reduction<br>(Day 180)</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">46%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">LDL-C Reduction<br>(Low dose)</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-gray-600 dark:text-gray-400">45%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">ApoB<br>Reduction</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">30%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="text-center p-4 bg-white dark:bg-gray-800 rounded-lg">
                            <div class="text-2xl font-bold text-green-600 dark:text-green-400">88%</div>
                            <div class="text-xs text-gray-600 dark:text-gray-400">Projected<br>CAD Risk↓</div>
                        </div>
                    </div>

                    <div class="bg-gray-50 dark:bg-gray-800 rounded-lg p-4">
                        <h4 class="text-sm font-medium text-gray-900 dark:text-white mb-3">Durability Profile</h4>
                        <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                            <li><strong class="text-gray-900 dark:text-white">Primate Data:</strong> >2.5 years sustained effect with no rebound</li>
                            <li><strong class="text-gray-900 dark:text-white">Human Projection:</strong> Expected lifelong effect from single infusion</li>
                            <li><strong class="text-gray-900 dark:text-white">Editing Coverage:</strong> 50-70% hepatocytes edited at therapeutic doses</li>
                            <li><strong class="text-gray-900 dark:text-white">Genetic Comparison:</strong> Mimics PCSK9 R46L carriers (88% lower CAD risk)</li>
                        </ul>
                    </div>
                </div>
            </div>

            <!-- Safety Tab -->
            <div class="tab-content hidden" id="safety">
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-red-50 to-pink-50 dark:from-red-900/20 dark:to-pink-900/20">
                    <p class="text-gray-700 dark:text-gray-300">
                        <span class="text-lg mr-2">⚠️</span>
                        <strong>Critical Safety Event:</strong> Heart-1 paused April 2024 due to Grade 3 ALT elevation and thrombocytopenia at 0.6 mg/kg dose. 
                        Led to complete redesign with VERVE-102.
                    </p>
                </div>

                <!-- Safety Grid -->
                <div class="grid grid-cols-2 md:grid-cols-3 lg:grid-cols-6 gap-4 mb-8">
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-red-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white">Grade 3</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">ALT Elevation<br>(Led to pause)</div>
                    </div>
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-red-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white">Low Platelets</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">Thrombocytopenia<br>(0.6 mg/kg)</div>
                    </div>
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-green-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white"><0.1%</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">Off-Target Edits<br>(WGS validated)</div>
                    </div>
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-green-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white">Minimal</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">Germline Risk<br>(No gonadal uptake)</div>
                    </div>
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-amber-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white">70%</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">Pre-existing Anti-Cas9<br>(Managed w/ steroids)</div>
                    </div>
                    <div class="bg-white dark:bg-gray-800 rounded-lg p-4 border-l-4 border-amber-500">
                        <div class="text-lg font-bold text-gray-900 dark:text-white">20-30%</div>
                        <div class="text-xs text-gray-600 dark:text-gray-400">Infusion Reactions<br>(Mild, transient)</div>
                    </div>
                </div>

                <!-- Long-term Monitoring -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Long-term Monitoring Requirements</h3>
                    <ul class="space-y-3">
                        <li class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">5-15 Year Follow-up:</strong> All patients in mandatory registry
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Cancer Surveillance:</strong> Annual screening for hepatocellular carcinoma
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Genomic Monitoring:</strong> Periodic WGS for emergent off-targets
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Liver Function:</strong> Quarterly LFTs year 1, then biannual
                        </li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Reproductive Health:</strong> Counseling on theoretical germline risks
                        </li>
                    </ul>
                </div>

                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-green-50 to-emerald-50 dark:from-green-900/20 dark:to-emerald-900/20">
                    <p class="text-gray-700 dark:text-gray-300">
                        <span class="text-lg mr-2">✓</span>
                        <strong>Safety Advantages vs Other Gene Therapies:</strong> No double-strand DNA breaks (unlike CRISPR), no viral vectors, 
                        liver-specific targeting, single nucleotide change only, precedent from healthy PCSK9 LOF humans.
                    </p>
                </div>

                <!-- Brain Safety -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Brain Safety & Low Cholesterol</h3>
                    <p class="text-sm text-gray-600 dark:text-gray-400 mb-4">
                        PCSK9 inhibition doesn't cross blood-brain barrier. Brain cholesterol is synthesized independently from plasma LDL.
                    </p>
                    <ul class="space-y-2">
                        <li class="text-sm text-gray-600 dark:text-gray-400">• Genetic PCSK9 knockouts show no cognitive deficits</li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">• Meta-analyses of PCSK9 inhibitors (LDL <20 mg/dL) show no dementia risk over 5+ years</li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">• All trials monitor neurocognition - no signals reported</li>
                        <li class="text-sm text-gray-600 dark:text-gray-400">• EBBINGHAUS study (evolocumab) confirmed cognitive safety</li>
                    </ul>
                </div>
            </div>

            <!-- Commercial Tab -->
            <div class="tab-content hidden" id="commercial">
                <div class="glass rounded-2xl p-8 mb-8 border border-gray-200 dark:border-gray-700 text-center">
                    <div class="text-4xl font-bold bg-gradient-to-r from-amber-600 to-orange-600 bg-clip-text text-transparent mb-2">
                        $1-2 Million
                    </div>
                    <div class="text-gray-600 dark:text-gray-400">Expected upfront pricing, justified by lifetime benefit vs ~$100K+ in chronic drugs/events over decades</div>
                    <div class="text-sm text-gray-500 dark:text-gray-500 mt-2">Payment models likely include annuities, outcomes-based rebates</div>
                </div>

                <!-- Market Metrics -->
                <div class="grid grid-cols-2 md:grid-cols-4 gap-6 mb-8">
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 text-center">
                        <div class="text-2xl font-bold text-indigo-600 dark:text-indigo-400">~1M</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">US HeFH/ASCVD Patients</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 text-center">
                        <div class="text-2xl font-bold text-amber-600 dark:text-amber-400">30-50%</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Initial Approval Rate</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 text-center">
                        <div class="text-2xl font-bold text-green-600 dark:text-green-400">15-20 yrs</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Break-even vs Chronic Rx</div>
                    </div>
                    <div class="glass rounded-xl p-6 border border-gray-200 dark:border-gray-700 text-center">
                        <div class="text-2xl font-bold text-purple-600 dark:text-purple-400">$2-3B</div>
                        <div class="text-sm text-gray-600 dark:text-gray-400">Peak Sales (Base Case)</div>
                    </div>
                </div>

                <!-- Reimbursement Challenges -->
                <div class="grid grid-cols-1 lg:grid-cols-2 gap-8 mb-8">
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Reimbursement Challenges</h3>
                        <ul class="space-y-2">
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">High upfront cost:</strong> Budget impact concerns for payers
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Insurance churn:</strong> Patient may switch insurers after cure
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Irreversibility:</strong> Ethical and practical concerns
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Prior auth:</strong> Extensive documentation, step therapy failures required
                            </li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Coverage restrictions:</strong> Initially only severe cases with multiple therapy failures
                            </li>
                        </ul>
                    </div>
                    
                    <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700">
                        <h3 class="text-lg font-medium text-gray-900 dark:text-white mb-4">Delivery Infrastructure</h3>
                        <ul class="space-y-2">
                            <li class="text-sm text-gray-600 dark:text-gray-400">• Initially at specialized centers (like CAR-T model)</li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">• Medical benefit, not pharmacy</li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">• Eventually may expand to infusion centers</li>
                            <li class="text-sm text-gray-600 dark:text-gray-400">• Requires long-term follow-up infrastructure</li>
                        </ul>
                    </div>
                </div>

                <!-- Market Scenarios Table -->
                <div class="glass rounded-2xl overflow-hidden border border-gray-200 dark:border-gray-700">
                    <div class="p-6 border-b border-gray-200 dark:border-gray-700">
                        <h3 class="text-xl font-medium text-gray-900 dark:text-white">Market Scenarios</h3>
                    </div>
                    <div class="overflow-x-auto">
                        <table class="w-full">
                            <thead class="bg-gray-50 dark:bg-gray-800 border-b border-gray-200 dark:border-gray-700">
                                <tr>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Timeframe</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Conservative</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Base Case</th>
                                    <th class="px-6 py-4 text-left text-xs font-medium text-gray-700 dark:text-gray-300 uppercase tracking-wider">Optimistic</th>
                                </tr>
                            </thead>
                            <tbody class="divide-y divide-gray-200 dark:divide-gray-700">
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">2025-2027</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Clinical trials only</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Phase 2/3 progression</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Accelerated approval pathway</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">2028-2030</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Limited HoFH approval</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">HeFH approval, slow uptake</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Broad HeFH use, ASCVD trials</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">2030-2035</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Niche for severe cases</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Standard for genetic dyslipidemia</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">Primary prevention consideration</td>
                                </tr>
                                <tr class="hover:bg-gray-50 dark:hover:bg-gray-800 transition-colors">
                                    <td class="px-6 py-4 text-sm font-medium text-gray-900 dark:text-white">Peak Sales</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">$500M</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">$2-3B</td>
                                    <td class="px-6 py-4 text-sm text-gray-600 dark:text-gray-400">$5B+</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- Future Outlook Tab -->
            <div class="tab-content hidden" id="future">
                <!-- Critical Success Factors -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Critical Success Factors</h3>
                    <div class="grid grid-cols-1 lg:grid-cols-2 gap-4">
                        <div class="bg-gray-50 dark:bg-gray-800 rounded-lg p-4">
                            <h4 class="text-sm font-medium text-gray-900 dark:text-white mb-3">What Must Go Right</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>• No long-term adverse effects over 5+ years</li>
                                <li>• Truly permanent LDL reduction demonstrated</li>
                                <li>• Consistent, scalable production achieved</li>
                                <li>• FDA/EMA satisfied with safety profile</li>
                                <li>• Sustainable reimbursement models developed</li>
                                <li>• "Gene editing" fears overcome through transparency</li>
                            </ul>
                        </div>
                        <div class="bg-red-50 dark:bg-red-900/20 rounded-lg p-4 border-l-4 border-red-500">
                            <h4 class="text-sm font-medium text-gray-900 dark:text-white mb-3">Key Risks</h4>
                            <ul class="space-y-2 text-sm text-gray-600 dark:text-gray-400">
                                <li>• Unknown long-term effects</li>
                                <li>• Potential for delayed adverse events</li>
                                <li>• Regulatory delays</li>
                                <li>• Public/physician resistance to irreversible therapy</li>
                                <li>• Competition from safer/simpler approaches</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-green-50 to-emerald-50 dark:from-green-900/20 dark:to-emerald-900/20">
                    <p class="text-gray-700 dark:text-gray-300">
                        <span class="text-lg mr-2">✓</span>
                        <strong>Why Lilly's Acquisition Makes Sense:</strong> Hedging across entire PCSK9 landscape, access to transformative technology, 
                        leverage existing CV infrastructure, first-mover in gene editing for common diseases, platform potential beyond PCSK9.
                    </p>
                </div>

                <!-- Precedents & Competition -->
                <div class="glass rounded-2xl p-6 mb-8 border border-gray-200 dark:border-gray-700">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-6">Precedents & Competition</h3>
                    
                    <div class="grid grid-cols-1 gap-4">
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-6 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="flex justify-between items-start mb-3">
                                <h4 class="text-lg font-medium text-gray-900 dark:text-white">Casgevy (Vertex/CRISPR)</h4>
                                <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                    FDA/EMA 2023
                                </span>
                            </div>
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                First CRISPR therapy approved for sickle cell. Price: $2.2M. Ex vivo editing (not in vivo like VERVE). 
                                Shows regulatory pathway possible, high price accepted for genetic diseases.
                            </p>
                            <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 mt-3 inline-block">
                                View FDA Announcement →
                            </a>
                        </div>
                        
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-6 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="flex justify-between items-start mb-3">
                                <h4 class="text-lg font-medium text-gray-900 dark:text-white">NTLA-2001 (Intellia)</h4>
                                <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-blue-100 dark:bg-blue-900/30 text-blue-800 dark:text-blue-400">
                                    Phase 3
                                </span>
                            </div>
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                In vivo CRISPR for ATTR amyloidosis. 87% TTR reduction, no major safety issues. 
                                Most similar precedent - shows in vivo editing feasible.
                            </p>
                            <a href="https://clinicaltrials.gov/search?intr=NTLA-2001" 
                               target="_blank" 
                               class="text-xs text-indigo-600 dark:text-indigo-400 hover:text-indigo-800 mt-3 inline-block">
                                View Clinical Trials →
                            </a>
                        </div>
                        
                        <div class="bg-white dark:bg-gray-800 rounded-lg p-6 border border-gray-200 dark:border-gray-600 hover:shadow-lg transition-shadow">
                            <div class="flex justify-between items-start mb-3">
                                <h4 class="text-lg font-medium text-gray-900 dark:text-white">Zolgensma (Novartis)</h4>
                                <span class="inline-flex items-center px-2.5 py-0.5 rounded-full text-xs font-medium bg-green-100 dark:bg-green-900/30 text-green-800 dark:text-green-400">
                                    FDA/EMA 2019
                                </span>
                            </div>
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                One-time AAV gene therapy for SMA. Price: $2.1M. 
                                Payer acceptance of high-cost cures, but 20-30% abandonment rate.
                            </p>
                        </div>
                    </div>
                </div>

                <!-- Bottom Line Assessment -->
                <div class="glass rounded-2xl p-6 border border-gray-200 dark:border-gray-700 bg-gradient-to-r from-indigo-50 to-purple-50 dark:from-indigo-900/20 dark:to-purple-900/20">
                    <h3 class="text-xl font-medium text-gray-900 dark:text-white mb-4">Strategic Outlook</h3>
                    <div class="space-y-3">
                        <p class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Near-term (2025-2027):</strong> Minimal commercial impact - still in trials
                        </p>
                        <p class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Medium-term (2028-2030):</strong> Potential approval for severe genetic dyslipidemia
                        </p>
                        <p class="text-sm text-gray-600 dark:text-gray-400">
                            <strong class="text-gray-900 dark:text-white">Long-term (2030+):</strong> Could revolutionize CV prevention if safety proven
                        </p>
                        <div class="pt-4 mt-4 border-t border-indigo-300 dark:border-indigo-600">
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Probability of Success:</strong> ~40-50% for HeFH indication by 2030
                            </p>
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Market Disruption:</strong> Extreme if successful, minimal if safety issues emerge
                            </p>
                            <p class="text-sm text-gray-600 dark:text-gray-400">
                                <strong class="text-gray-900 dark:text-white">Strategic Value:</strong> Critical optionality for future of lipid management
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </div>

    <!-- JavaScript -->
    <script>
        function toggleTheme() {
            document.body.classList.toggle('dark');
            localStorage.setItem('theme', document.body.classList.contains('dark') ? 'dark' : 'light');
        }

        // Load saved theme
        if (localStorage.getItem('theme') === 'dark' || (!localStorage.getItem('theme') && window.matchMedia('(prefers-color-scheme: dark)').matches)) {
            document.body.classList.add('dark');
        }

        function showTab(tabName, event) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => {
                tab.classList.add('hidden');
                tab.classList.remove('active');
            });
            
            // Update button styles
            const buttons = document.querySelectorAll('.tab-btn');
            buttons.forEach(btn => {
                btn.classList.remove('bg-indigo-600', 'text-white');
                btn.classList.add('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            });
            
            // Show selected tab
            document.getElementById(tabName).classList.remove('hidden');
            document.getElementById(tabName).classList.add('active');
            
            // Style active button
            event.target.classList.remove('bg-gray-100', 'dark:bg-gray-800', 'text-gray-700', 'dark:text-gray-300');
            event.target.classList.add('bg-indigo-600', 'text-white');
        }
    </script>
</body>
</html>